Eintrag weiter verarbeiten
The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
Gespeichert in:
| Zeitschriftentitel: | Brain and Behavior |
|---|---|
| Personen und Körperschaften: | |
| In: | Brain and Behavior, 7, 2017, 6 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Madsen, Claus Madsen, Claus |
|---|---|
| author |
Madsen, Claus |
| spellingShingle |
Madsen, Claus Brain and Behavior The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis Behavioral Neuroscience |
| author_sort |
madsen, claus |
| spelling |
Madsen, Claus 2162-3279 2162-3279 Wiley Behavioral Neuroscience http://dx.doi.org/10.1002/brb3.696 <jats:title>Abstract</jats:title><jats:p>The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of relapsing‐remitting multiple sclerosis (<jats:styled-content style="fixed-case">RRMS</jats:styled-content>) with a significant impact on the approach to modern multiple sclerosis (<jats:styled-content style="fixed-case">MS</jats:styled-content>) care. Key learnings and perspectives from the early days of disease modifying therapies in <jats:styled-content style="fixed-case">MS</jats:styled-content> have improved the knowledge base of <jats:styled-content style="fixed-case">MS</jats:styled-content>, need for treatment, and patient care. The continuous development of interferons over the past two decades outlines a journey with increased understanding of the pharmacodynamics and pharmacokinetic mechanisms of interferons, leading to innovative formulations with an improved benefit/risk profile.</jats:p> The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis Brain and Behavior |
| doi_str_mv |
10.1002/brb3.696 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9icmIzLjY5Ng |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9icmIzLjY5Ng |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2017 |
| imprint_str_mv |
Wiley, 2017 |
| issn |
2162-3279 |
| issn_str_mv |
2162-3279 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
madsen2017theinnovativedevelopmentininterferonbetatreatmentsofrelapsingremittingmultiplesclerosis |
| publishDateSort |
2017 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Brain and Behavior |
| source_id |
49 |
| title |
The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| title_unstemmed |
The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| title_full |
The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| title_fullStr |
The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| title_full_unstemmed |
The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| title_short |
The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| title_sort |
the innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| topic |
Behavioral Neuroscience |
| url |
http://dx.doi.org/10.1002/brb3.696 |
| publishDate |
2017 |
| physical |
|
| description |
<jats:title>Abstract</jats:title><jats:p>The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of relapsing‐remitting multiple sclerosis (<jats:styled-content style="fixed-case">RRMS</jats:styled-content>) with a significant impact on the approach to modern multiple sclerosis (<jats:styled-content style="fixed-case">MS</jats:styled-content>) care. Key learnings and perspectives from the early days of disease modifying therapies in <jats:styled-content style="fixed-case">MS</jats:styled-content> have improved the knowledge base of <jats:styled-content style="fixed-case">MS</jats:styled-content>, need for treatment, and patient care. The continuous development of interferons over the past two decades outlines a journey with increased understanding of the pharmacodynamics and pharmacokinetic mechanisms of interferons, leading to innovative formulations with an improved benefit/risk profile.</jats:p> |
| container_issue |
6 |
| container_start_page |
0 |
| container_title |
Brain and Behavior |
| container_volume |
7 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792344819725500421 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:13:38.349Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=The+innovative+development+in+interferon+beta+treatments+of+relapsing%E2%80%90remitting+multiple+sclerosis&rft.date=2017-06-01&genre=article&issn=2162-3279&volume=7&issue=6&jtitle=Brain+and+Behavior&atitle=The+innovative+development+in+interferon+beta+treatments+of+relapsing%E2%80%90remitting+multiple+sclerosis&aulast=Madsen&aufirst=Claus&rft_id=info%3Adoi%2F10.1002%2Fbrb3.696&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792344819725500421 |
| author | Madsen, Claus |
| author_facet | Madsen, Claus, Madsen, Claus |
| author_sort | madsen, claus |
| container_issue | 6 |
| container_start_page | 0 |
| container_title | Brain and Behavior |
| container_volume | 7 |
| description | <jats:title>Abstract</jats:title><jats:p>The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of relapsing‐remitting multiple sclerosis (<jats:styled-content style="fixed-case">RRMS</jats:styled-content>) with a significant impact on the approach to modern multiple sclerosis (<jats:styled-content style="fixed-case">MS</jats:styled-content>) care. Key learnings and perspectives from the early days of disease modifying therapies in <jats:styled-content style="fixed-case">MS</jats:styled-content> have improved the knowledge base of <jats:styled-content style="fixed-case">MS</jats:styled-content>, need for treatment, and patient care. The continuous development of interferons over the past two decades outlines a journey with increased understanding of the pharmacodynamics and pharmacokinetic mechanisms of interferons, leading to innovative formulations with an improved benefit/risk profile.</jats:p> |
| doi_str_mv | 10.1002/brb3.696 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9icmIzLjY5Ng |
| imprint | Wiley, 2017 |
| imprint_str_mv | Wiley, 2017 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 2162-3279 |
| issn_str_mv | 2162-3279 |
| language | English |
| last_indexed | 2024-03-01T17:13:38.349Z |
| match_str | madsen2017theinnovativedevelopmentininterferonbetatreatmentsofrelapsingremittingmultiplesclerosis |
| mega_collection | Wiley (CrossRef) |
| physical | |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Brain and Behavior |
| source_id | 49 |
| spelling | Madsen, Claus 2162-3279 2162-3279 Wiley Behavioral Neuroscience http://dx.doi.org/10.1002/brb3.696 <jats:title>Abstract</jats:title><jats:p>The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of relapsing‐remitting multiple sclerosis (<jats:styled-content style="fixed-case">RRMS</jats:styled-content>) with a significant impact on the approach to modern multiple sclerosis (<jats:styled-content style="fixed-case">MS</jats:styled-content>) care. Key learnings and perspectives from the early days of disease modifying therapies in <jats:styled-content style="fixed-case">MS</jats:styled-content> have improved the knowledge base of <jats:styled-content style="fixed-case">MS</jats:styled-content>, need for treatment, and patient care. The continuous development of interferons over the past two decades outlines a journey with increased understanding of the pharmacodynamics and pharmacokinetic mechanisms of interferons, leading to innovative formulations with an improved benefit/risk profile.</jats:p> The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis Brain and Behavior |
| spellingShingle | Madsen, Claus, Brain and Behavior, The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis, Behavioral Neuroscience |
| title | The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| title_full | The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| title_fullStr | The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| title_full_unstemmed | The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| title_short | The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| title_sort | the innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| title_unstemmed | The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis |
| topic | Behavioral Neuroscience |
| url | http://dx.doi.org/10.1002/brb3.696 |